iC9-CAR19 T cells in Relapsed/Refractory B-cell Lymphoma

Phase 1, open-label trial of IC9-CAR19 in B cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Number of Participants With Treatment-emergent Grade >= 3 Adverse Events Per National Cancer Institute's Common Terminology Criteria at 4 weeks, Number of Participants With Treatment-emergent Grade >= 3 Adverse Events Per Cytokine Release Syndrome (CRS) at 4 weeks and 1 more. Started Mar 2019; status: active, not recruiting.